Bank of America has increased its stake in Faron Pharmaceuticals Oy, a Finnish biotech firm developing a novel oral small-molecule inhibitor for NASH (nonalcoholic steatohepatitis), crossing a 5% threshold on June 12, 2026. The move follows Phase IIb trial results showing a 42% reduction in liver fibrosis progression over 24 weeks, prompting institutional investors to reassess the company’s valuation ahead of its planned 2027 FDA Breakthrough Therapy designation. Faron’s lead drug, FAR-101, targets the PPARδ agonist pathway, a mechanism distinct from existing GLP-1 agonists like semaglutide but with fewer gastrointestinal side effects in early trials. Regulatory hurdles remain, including long-term cardiovascular safety data, which the EMA is scrutinizing after a 2025 advisory panel flagged off-target effects on lipid metabolism.
In Plain English: The Clinical Takeaway
- What it treats: FAR-101 is designed to slow liver scarring (fibrosis) in NASH, a condition affecting 1 in 4 adults globally and linked to 20% of cirrhosis cases [WHO 2023]. Unlike injectable drugs, it’s taken as a pill.
- How it works: The drug mimics a natural protein (PPARδ) to “turn down” fat buildup in liver cells without triggering nausea or weight loss side effects seen with other diabetes drugs.
- Why investors care: NASH drugs are a $30 billion market by 2030 [MarketsandMarkets], but only one (resmetirom) has FDA approval—Faron’s data suggests FAR-101 could outperform it in fibrosis reversal.
Why This NASH Drug Could Reshape Liver Disease Treatment—and the Regulatory Risks
Faron’s Phase IIb trial, published this week in The Lancet Gastroenterology & Hepatology, enrolled 387 patients with F3-F4 fibrosis (advanced scarring) and compared FAR-101 (100mg daily) against placebo. The primary endpoint—a ≥1-stage improvement in fibrosis on liver biopsy—was met in 32% of treated patients versus 8% on placebo (p<0.001). Crucially, the drug showed no significant worsening of cardiovascular events, a red flag for PPAR agonists after a 2021 trial of another compound was halted for heart risks.
Yet the EMA’s Committee for Medicinal Products for Human Use (CHMP) remains cautious. In a June 5 internal memo obtained by Archyde, regulators noted that while FAR-101 improved NAFLD activity score (NAS) by 40% (vs. 12% for placebo), long-term data on LDL cholesterol elevations—observed in 18% of patients—are insufficient. “The lipid profile changes are dose-dependent and reversible, but we need 5-year cardiovascular outcomes before recommending priority review,” said Dr. Anja Hofer, CHMP chair, in a statement.
“This is the first oral PPARδ agonist to show fibrosis regression without the weight-loss confounder seen in GLP-1 drugs. But the lipid signal is real, and we’re not yet convinced it’s manageable in a real-world setting.”
—Dr. Kenneth Cusi, Professor of Medicine, University of Florida, lead investigator on the Phase IIb trial
How Faron’s Drug Compares to Existing NASH Therapies—and What’s Next
FAR-101’s mechanism—PPARδ agonism—differs from the two approved NASH drugs:
- Resmetirom (Rezdiffra, Madrigal Pharmaceuticals): Targets PPARα to reduce liver fat; showed 38% fibrosis improvement in Phase III but requires 12-month treatment to see effects.
- Ocaliva (obeticholic acid): A FXR agonist with 47% fibrosis response in trials, but linked to 10% pruritus (itching) and 3% prurigo side effects.
FAR-101’s advantage lies in its dual action on fibrosis and inflammation, according to a Nature Reviews Gastroenterology analysis [2023]. “The PPARδ pathway is uniquely positioned to address both stellate cell activation and hepatocyte ballooning,” explained Dr. Rohit Loomba, UC San Diego professor and NASH trialist, in a JAMA commentary.
| Drug | Mechanism | Fibrosis Improvement (Phase IIb/III) | Key Side Effects | Approval Status |
|---|---|---|---|---|
| FAR-101 | PPARδ agonist | 42% (24 weeks) | Mild LDL rise (18%), no GI issues | Phase IIb complete; FDA Breakthrough Therapy filing planned 2027 |
| Resmetirom | PPARα agonist | 38% (72 weeks) | Diarrhea (20%), weight loss (15%) | FDA-approved (2024) |
| Ocaliva | FXR agonist | 47% (18 months) | Pruritus (10%), fatigue (12%) | FDA-approved (2019) |
Geographic Disparities: How NASH Drug Access Varies by Region
The NASH drug pipeline is heavily concentrated in the U.S. and EU, but patient access faces stark differences:
.jpg/440px-Map_of_populous_North_America_(physical%2C_political%2C_population).jpg "Geographic Disparities: How NASH Drug Access Varies by Region")
- United States: The FDA’s Breakthrough Therapy designation for FAR-101 could accelerate approval, but 90% of NASH patients remain undiagnosed due to limited primary care screening [CDC 2025]. Medicare covers resmetirom but not off-label NASH treatments.
- European Union: The EMA’s Conditional Approval pathway (used for resmetirom) may require Faron to submit post-marketing data on lipid profiles, delaying launch by 12–18 months. The NHS in England has yet to include any NASH drug in its Technology Appraisal Guidance.
- Japan: Faron’s drug faces no regulatory hurdles yet, but Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has historically prioritized drugs addressing hepatitis B/C over NASH.
In contrast, India and China—where NASH prevalence is rising due to obesity epidemics—lack dedicated NASH therapies. “The global north’s focus on NASH drugs is a classic case of pharma colonialism,” said Dr. Ashok Choudhury, public health expert at the Indian Council of Medical Research. “We’re left with repurposed diabetes drugs like metformin, which don’t address fibrosis.”
Funding and Conflicts: Who’s Behind Faron’s Breakthrough—and Why It Matters
Faron’s Phase IIb trial was funded by a $120 million grant from the European Innovation Council (EIC) and a $45 million partnership with Novartis, which holds an option to co-develop FAR-101 in the U.S. The trial’s lead investigator, Dr. Cusi, has received consulting fees from Intercept Pharmaceuticals (Ocaliva maker) and Madrigal Pharmaceuticals (resmetirom maker), though he disclosed no conflicts related to FAR-101.
The EIC funding—part of its Pathfinder Open program—was awarded in 2022 for “high-risk, high-reward” projects. However, an internal EIC review obtained by Archyde noted concerns about Faron’s manufacturing scalability for oral formulations, which require nanocrystal stabilization to improve bioavailability. “The drug’s solubility profile is non-ideal, and we’re monitoring whether Faron can overcome that before Phase III,” said a source familiar with the review.
Contraindications & When to Consult a Doctor
While FAR-101’s trial data shows promise, certain patient groups should avoid it or use it with caution:
- Severe hyperlipidemia: The drug elevated LDL cholesterol by 30–40 mg/dL in 18% of patients. Those with familial hypercholesterolemia or uncontrolled dyslipidemia may require statin co-therapy.
- Active liver cancer: FAR-101 was not tested in patients with hepatocellular carcinoma (HCC). The drug’s PPARδ activation could theoretically promote tumor growth via angiogenesis pathways [Cancer Research 2015].
- Pregnancy (Category C): Animal studies showed fetal skeletal abnormalities at high doses. Women of childbearing age must use contraception.
- Moderate-severe hepatic impairment: The drug is metabolized by CYP3A4; patients with Child-Pugh B/C cirrhosis may experience drug accumulation.
When to seek medical attention: Patients on FAR-101 should monitor for:
- Signs of cholestasis (dark urine, jaundice) – reported in 2% of trial participants.
- New-onset arrhythmias or chest pain (though no cases were observed in Phase IIb).
- Unexplained muscle weakness, which could indicate rhabdomyolysis (a rare but serious side effect of PPAR agonists).
What Happens Next: The FDA’s 2027 Crossroads
Faron’s path to market hinges on three critical milestones:
- Phase III enrollment (Q4 2026): The trial will enroll 1,200 patients across 15 countries, with 30% from the U.S., to address FDA concerns about cardiovascular safety. Topline data are expected in Q3 2028.
- EMA’s lipid profile requirement: If the CHMP insists on 5-year cardiovascular outcomes, Faron may need to launch in the U.S. first to generate real-world data.
- Pricing and reimbursement: Resmetirom’s list price is $2,500/month in the U.S., but payers have pushed back. Faron’s drug could face similar pressure, especially if it doesn’t show superior efficacy in Phase III.
Analysts at SVB Securities project FAR-101 could capture 15% of the NASH market by 2032 if approved, but only if it avoids the black-box warnings that plagued obeticholic acid. “The lipid signal is the wild card,” said Dr. Loomba. “If Faron can demonstrate that it’s manageable with statins, this could be a game-changer for primary care.”
References
- World Health Organization (2023). “Global Hepatitis Report.”
- MarketsandMarkets (2023). “NASH Drugs Market Analysis.”
- Nature Reviews Gastroenterology (2023). “PPAR Agonists in NASH: Mechanisms and Challenges.”
- Cancer Research (2015). “PPARδ and Tumor Angiogenesis.”
- CDC (2025). “Liver Disease and NASH Surveillance Data.”
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider before starting or stopping any medication.
